Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
20.73
-0.86 (-3.98%)
At close: Feb 21, 2025, 4:00 PM
20.95
+0.22 (1.06%)
After-hours: Feb 21, 2025, 7:24 PM EST
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 37.91, with a low estimate of 24 and a high estimate of 87. The average target predicts an increase of 82.88% from the current stock price of 20.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 5 | 5 |
| Hold | 1 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 11 | 11 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Deutsche Bank | Deutsche Bank | Strong Buy Initiates $31 | Strong Buy | Initiates | $31 | +49.54% | Feb 11, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $45 → $40 | Strong Buy | Maintains | $45 → $40 | +92.96% | Jan 28, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $28 → $24 | Buy | Maintains | $28 → $24 | +15.77% | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $87 | Strong Buy | Maintains | $90 → $87 | +319.68% | Jan 7, 2025 |
| Baird | Baird | Buy Initiates $31 | Buy | Initiates | $31 | +49.54% | Jan 7, 2025 |
Financial Forecast
Revenue This Year
8.87M
from 330.53M
Decreased by -97.32%
Revenue Next Year
34.54M
from 8.87M
Increased by 289.18%
EPS This Year
-2.78
from -1.06
EPS Next Year
-3.09
from -2.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 52.5M | 164.3M | 567.4M | |||
| Avg | 8.9M | 34.5M | 170.0M | |||
| Low | n/a | n/a | 15.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -84.1% | 1,751.8% | 1,543.0% | |||
| Avg | -97.3% | 289.2% | 392.1% | |||
| Low | - | - | -55.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.34 | -2.32 | -0.61 | |||
| Avg | -2.78 | -3.09 | -2.52 | |||
| Low | -3.08 | -3.61 | -3.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.